Category: Health Science
-
Leaping Forward: PredictMedix (PMED.C) partners with TechMahindra
Keynes once said that “the market can remain irrational longer than you can remain solvent”. Fundamentals departed market valuation long ago, but you could’ve at least expected market reaction to be in response to COVID-19 related news. Except it seems like that’s no longer the case.
-
Algernon Pharmaceuticals (AGN.C) gets ethical green light for human trials for COVID-19 fighter Ifenprodil
The scientific process isn’t exactly what you were taught in grade 4. There’s a lot more to it, owing to some historical—well, let’s call them what they are—atrocities, which have taken place as long as white lab-coats have been all the rage in knowledge-defining circles. This process is expensive in both time and money and…
-
Shroom Digest: Mushroom moves from MindMed, Yield Growth, New Wave, Yukoterre, Silo, EGF Theramed
This week’s digest of mushroom moves is a mixed bag of trash and glory, with the shrooms sector increasingly looking like the early days of the cannabis rush.
-
Xphyto (XPHY.C) just unlocked a pipeline of biosensor screening projects
Our early coverage of Xphyto reveals the following company trait: Xphyto says, “We’re going to do this” – and then they do it – quickly.
-
Predictmedix (PMED.C) inks deal to acquire a Telehealth company
Predictmedix and MobileWellbeing are attacking the Telehealth problem from different angles.
-
Xphyto (XPHY.C) advances delivery system for Parkinson’s drug
Vektor is now proceeding with process implementation for the manufacture of Rotigotine patches for human clinical studies.
-
I asked Twitter what tickers I should be writing about: Twitter had 35 ideas… here’s 6 of them
Ever get the feeling, looking at your watchlist, that you’re seeing the same thing over and over? That maybe there’s interesting stuff out there you just haven’t heard about yet? I put a simple question to Twitter today: “Give me a ticker symbol you think I should be writing about (limit one per person), three…
-
Predictmedix (PMED.C) killing it on new COVID-19 screening tech
I love it when a plan comes together. Predictmedix (PMED.C) continued to launch itself upward this week, jumping from $0.72 to $0.98 in just days, on the back of news it’s being used by a large events company, and financials that show a very short road to profitability. For those that haven’t been paying attention…
-
Biotech: Who Will Survive When The COVID-19 Hype Ends?
Over the last couple of months, companies have found a way to muster up an effort to align their objectives with helping society recover from this global pandemic – COVID-19. The result: share prices have soared like never before. The line up of biotech companies trying to come up with COVID-19 vaccines or cures is…